Veklury

Indicated For

COVID-19 hospitalized, COVID-19 high-risk non-hospitalized

About This Medication

# Gilead Advancing Access Patient Assistance Program Patient Guide: How to Get Veklury (remdesivir) at Low or No Cost ## About Veklury (remdesivir) **Veklury (remdesivir)** is an antiviral medication developed by Gilead Sciences to treat COVID-19 in certain patients. It works by stopping the SARS-CoV-2 virus from multiplying in the body, helping to reduce the severity and duration of illness. Administered intravenously, it's typically used in hospitalized patients or, in some cases, outpatients with mild-to-moderate COVID-19 who are at high risk for progression. Always follow your doctor's instructions for use, as dosing depends on your weight, kidney function, and treatment setting. This guide focuses on the **Gilead Advancing Access Patient Assistance Program (PAP)**, which provides **Veklury free of charge** to eligible uninsured patients in outpatient settings. For commercially insured patients, a separate co-pay program may reduce out-of-pocket costs. ## Who Qualifies for the Program? The program is designed for **uninsured U.S. residents** (including Puerto Rico and U.S. Territories) prescribed Veklury for outpatient use. Key eligibility includes: - No health insurance coverage. - Residency in the U.S., Puerto Rico, or U.S. Territories (proof may be required). - Meeting income guidelines, though exact thresholds are not publicly specified and determined by program specialists. - A valid prescription from a U.S. healthcare provider. Enrollment lasts **up to 12 months**, with ongoing checks to confirm you still qualify. If you gain insurance during this time, your eligibility may change. **Note:** This is specifically for outpatient Veklury; inpatient use may be covered differently by hospitals or other programs. ## Income Eligibility Breakdown Specific income thresholds (e.g., Federal Poverty Level percentages) for Veklury are not detailed online and vary by household size. Program specialists assess eligibility case-by-case during enrollment. Contact them at (800) 226-2056 for personalized details. Here's a general overview based on typical Gilead PAP structures (confirm with specialists): | Household Size | Estimated Income Limit | Notes | |---------------|-----------------------|-------| | Individual | Case-by-case | Uninsured outpatient only | | Couple | Case-by-case | Proof of income required (e.g., tax returns, pay stubs) | | Family of 3 | Case-by-case | Household income considered | | Family of 4+ | Case-by-case | Larger families may have adjusted limits | **Income proof** may include: last two pay stubs, W-2 forms, tax returns, or identification. Specialists will guide you. ## Insurance Requirements - **Uninsured patients**: Eligible for free Veklury via PAP in outpatient settings. - **Commercially insured**: May qualify for the Co-pay Savings Program to lower costs. - **Medicare/Medicaid**: Generally ineligible for PAP; explore government programs or hospital assistance. - Benefits investigations are available to check coverage. ## Step-by-Step Application Process Applying is straightforward and primarily **by phone** for Veklury support. Here's how: 1. **Get a Prescription**: Ask your doctor for Veklury in the outpatient setting. They must sign the enrollment form. 2. **Contact Gilead Advancing Access**: Call **(800) 226-2056** (Monday–Friday, 9 AM–8 PM ET). Specialists speak multiple languages. 3. **Provide Information**: Share your details, prescription info, income, residency, and insurance status (or lack thereof). Consent to verification. 4. **Submit Documents**: Fax enrollment form if requested (fax numbers provided on forms, e.g., 1-800-216-6857). Include: - Proof of identity (ID card). - Income docs (pay stubs, tax return, W-2). - Proof of residency if needed. - Doctor's signature and prescription. 5. **Eligibility Review**: Expect a decision in **2 business days** for faxed forms; phone may be faster. 6. **Notification**: You'll be called or notified via your preferred method. If approved, medication ships to a pharmacy or provider. Download forms from GileadAdvancingAccess.com if needed (English/Spanish available). ## Timeline and Delivery - **Review Time**: 2 business days for faxed forms; immediate for online/phone in some cases. - **Enrollment Duration**: Up to 12 months with periodic rechecks. - **Delivery**: Free medication sent to a dispensing pharmacy or your provider. Exact method confirmed post-approval. - Specialists coordinate to get you started quickly, especially for urgent needs. ## Alternatives if Denied or Ineligible - **Appeal**: Call (800) 226-2056 to discuss reasons and resubmit docs. - **Co-pay Program**: For commercial insurance. - **Other Resources**: - State AIDS Drug Assistance Programs (ADAP) if applicable. - Hospital financial aid or COVID-19 relief funds. - Nebulized GS-441524 or other antivirals (consult doctor; no biosimilars for Veklury). - Patient Access Network (PAN) Foundation or HealthWell Foundation for COVID treatments. - **No biosimilar alternatives** listed for Veklury. ## Important Disclaimer This guide is for informational purposes based on publicly available program details as of 2026. Gilead may change eligibility, forms, or the program without notice. Always verify with specialists at (800) 226-2056. Not medical advice—consult your doctor. Assistance not guaranteed; individual results vary. Gilead authorizes info sharing for eligibility only.

Program information last verified: March 30, 2026